109744-49-2

Basic information

• Product Name: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester
• Synonyms: (3R)-3-[(TERT-BUTYLDIMETHYLSILYL)OXY] PENTANEDIOATE-1-METHYLMONOESTER;B-6;(3R)-3-[(terbutyldimethylsilyl)oxy]pentanedioate-1-methylmonoester;J-4：(3R)-3-[(tert-butyldimethylsilyl)oxy] pentanedioate-1-methylmonoester;(3R)-3-[(t-Butyldimethylsilyl)oxy]pentanedioate-1-methylmonoester,J-4;(3R)-3-[(tert-butyldimethylsily)oxy]pentanedioate-1-Methylmonoester;(R)-3-(tert-Butyl-dimethyl-silanyloxy)-pentanedioicacidmonomethylester;(R)-3-((tert-ButyldiMethylsilyl)oxy)-5-Methoxy-5-oxopentanoic acid
• CAS NO: 109744-49-2
• Molecular Formula: C₁₂H₂₄O₅Si
• Molecular Weight: 276.4
• EINECS: 1312995-182-4
• Product Categories: rosuvastatin intermediates
• Mol File: 109744-49-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 327.412 °C at 760 mmHg
• Flash Point: 151.814 °C
• Appearance: /
• Density: 1.034 cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.447
• PKA: 4.11±0.10(Predicted)
• CAS DataBase Reference: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester(CAS DataBase Reference)
• NIST Chemistry Reference: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester(109744-49-2)
• EPA Substance Registry System: (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester(109744-49-2)

Safety Data

• Hazardous Substances Data: 109744-49-2(Hazardous Substances Data)

Usage

General Description

The chemical "(3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester" is an organic compound with a complex structure. It contains a (3R)-3-(tert-butyldimethylsilyl)oxy group as well as a pentanedioate-1-methyl monoester moiety. The tert-butyldimethylsilyl group is a protecting group often used in organic synthesis, while the pentanedioate-1-methyl monoester moiety suggests the presence of a pentanedioic acid derivative. (3R)-3-(tert-Butyldimethylsilyl)oxypentanedioate-1-methyl monoester is likely to have applications in organic synthesis, particularly in the protection and manipulation of functional groups. Its precise function and potential uses would depend on its specific chemical properties and reactivity.

InChI:InChI=1/C12H24O5Si/c1-12(2,3)18(5,6)17-9(7-10(13)14)8-11(15)16-4/h9H,7-8H2,1-6H3,(H,13,14)/t9-/m1/s1

Upstream product

• 90613-44-8 methyl 3-acetoxypentanedioate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 96555-56-5 (3S,1'S)-methyl 1'-phenylethyl 3-<(tert-butyldimethylsilyl)oxy>pentanedioate 
• 67-56-1 methanol 
• 131466-61-0 (3R)-3-<(tert-Butyldimethylsilyl)oxy>pentanedioic acid 1-<(R)-mandelic acid> ester 
• 7250-55-7 dimethyl 3-hydroxypentanedioate 
• 124-41-4 sodium methylate 
• 91424-40-7 3-(tert-butyldimethylsilyloxy)glutaric anhydride 
• 1350364-00-9 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate cyclohexylamine salt 
• 32328-03-3 diethyl 3-hydroxyglutarate 
• 91424-39-4 3-[[(1,1-Dimethylethyl)dimethylsilyl]-oxy]pentanedioic acid,diethyl ester 
• 140164-51-8 methyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-yl)acetate 
• 121980-45-8 (3R)-(-)-methyl 3-<(tert-butyldimethylsilyl)oxy>-4-formylbutanoate 

Downstream Products

• 147118-35-2 methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate 
• 1350364-18-9 C₁₅H₂₈O₇Si 
• 1350364-05-4 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate benzylamine salt 
• 1350364-00-9 hydrogen (3R)-1-methyl 3-[(tert-butyldimethylsilyl)-oxy]pentanedioate cyclohexylamine salt 
• 147118-39-6 methyl (3R,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoate 
• 182075-76-9 (R,E)-methyl 3-(tert-butyldimethylsilyloxy)-7-(2-cyclopropyl-4-(-4-fluorophenyl)-quinolin-3-yl)-5-oxohept-6-enoate 
• 917752-45-5 methyl (E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-3-hydroxy-5-oxo-6-heptenate 
• 1622873-98-6 C₃₂H₄₈FN₃O₆SSi 

Relevant articles and documents

Preparation method of high-purity statin drug intermediate

The invention relates to a preparation method of a high-purity statin drug intermediate. The preparation method is characterized in that 3-hydroxyl ethyl glutarate is used as the initial raw material to prepare (3R)-tert-butyl dimethyl silyloxy-5-oxo-6-triphenyl phosphine caproate (abbreviated as J6) through substitution reaction, hydrolysis reaction, cyclization reaction, resolution reaction, hydrogenation reaction, acylation reaction and Wittig reaction. The preparation method is mild in condition, stable in process, cheap in raw material, easy in raw material obtaining, easy in three-waste treatment, low in preparation cost, high in product purity and suitable for industrial production.

A synthetic method of the compound

The invention relates to the field of chemistry and in particular relates to the field of medical chemistry. The invention aims to find a novel synthetic route suitable for Vb compounds in industrial production and adaptively provides a specific implementation process of the novel synthetic route, so that high-purity low-cost Vb compounds can be obtained. The compound Vb is prepared by taking a compound I as an initial raw material, so that the traditional Vb synthetic process is replaced. With the adoption of the synthetic route disclosed by the invention, the invention has the advantages that 1, dangerous and expensive butyl lithium is not used; 2, hydrogenation is avoided, and expensive metal palladium is avoided; and 3, more important, debenzylation byproducts in the hydrogenation are avoided. Meanwhile, because the price of the compound I is low, after the synthetic route disclosed by the invention is adopted, the industrial production need of the obtained high-purity low-cost compound V can be met.

AN IMPROVED PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF HMG-COA REDUCTASE INHIBITORS

The present invention relates to an improved process for the preparation of intermediates of HMG-CoA reductase inhibitors of Formulae-IXa or IXb and further conversion to HMG-CoA reductase inhibitors and pharmaceutically acceptable salts thereof.